In order to request this CME/CE activity for your center, please contact Samantha Zelasko at SZelasko@gotoper.com

April 15th, 1:30 pm - 2:30 pm ET

Register Here

April 22nd, 11:00 am - 12:00 pm ET

Register Here

EGFR exon 20 insertion mutations are the third most common oncogenic molecular aberration associated with EGFR in patients with non-small cell lung cancer (NCSLC). These mutations are generally insensitive to classical EGFR kinase inhibitors. New advances in therapy have led to approval of 2 novel treatment options in this setting.

The goal of this Oncology Best Practice™ series is to provide up-to-date recommendations for testing, treatment selection, and management of toxicities related to patients with EGFR exon 20 insertion mutations. This series of live, virtual meetings will include multiple formats for learning, including data presentations, case presentations, and faculty Q&A.

• Engage leading experts in the management of exon 20 insertion mutations
• Learn how to best select between available options
• Find out the best way to identify exon 20 insertion mutations in patients with lung cancer

This CME program is supported by educational grants from Janssen Biotech Inc., administered by Janssen Scientific Affairs, LLC. and Takeda Oncology.

This educational activity is directed toward community oncologists, NP/PAs, pharmacists, payers, and nurses.

Upon completion of this activity, participants will be able to:

• Determine optimal molecular testing strategies for patients with NSCLC and EGFR exon 20 insertions along the disease continuum
• Explain clinical trial data from studies that have evaluated EGFR exon 20-targeted agents in for patients with advanced NSCLC and EGFR exon 20 insertions
• Apply personalized treatment approaches for patients with EGFR exon 20 insertions across multiple lines of therapy
• Delineate multidisciplinary strategies to identify and manage treatment-related adverse events associated with EGFR exon 20-targeted regimens

Catherine A. Shu, MD

Associate Professor of Medicine at CUMC
Clinical Director, Thoracic Medical Oncology Service
New York-Presbyterian / Columbia University Irving Medical Center
New York, NY

Physicians’ Education Resource (PER) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity will be made available for 1.0 AMA PRA Category 1.0 Credits.

Physicians' Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.0 Contact Hours